Literature DB >> 19532134

Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.

Olga S Kustikova1, Bernhard Schiedlmeier, Martijn H Brugman, Maike Stahlhut, Stefan Bartels, Zhixiong Li, Christopher Baum.   

Abstract

In gene therapeutic approaches targeting hematopoietic cells, insertional mutagenesis may provoke clonal dominance with potential progress to overt leukemia. To investigate the contribution of cell-intrinsic features and determine the frequency of insertional proto-oncogene activation, we sorted hematopoietic subpopulations before transduction with replication-deficient gamma-retroviral vectors and studied the clonal repertoire in transplanted C57BL/6J mice. Progressive clonal dominance only developed in the progeny of populations with intrinsic stem cell potential, where expanding clones with insertional upregulation of proto-oncogenes such as Evi1 were retrieved with a frequency of approximately 10(-4). Longitudinal studies by high-throughput sequencing and locus-specific quantitative PCR showed clones with >50-fold expansion between weeks 5 and 31 after transplantation. In contrast, insertional events in proto-oncogenes did not endow the progeny of multipotent or myeloid-restricted progenitors with the potential for clonal dominance (risk <10(-6)). Transducing sorted hematopoietic stem cells (HSCs) with self-inactivating (SIN) lentiviral vectors in short-term cultures improved chimerism, and although clonal dominance developed, there was no evidence for insertional events in the vicinity of proto-oncogenes as the underlying cause. We conclude that cell-intrinsic properties cooperate with vector-related features to determine the incidence and consequences of insertional mutagenesis. Furthermore, our study offers perspectives for refinement of animal experiments in the assessment of vector-related genotoxicity.

Entities:  

Mesh:

Year:  2009        PMID: 19532134      PMCID: PMC2835258          DOI: 10.1038/mt.2009.134

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Murine leukemia induced by retroviral gene marking.

Authors:  Zhixiong Li; Jochen Düllmann; Bernd Schiedlmeier; Manfred Schmidt; Christof von Kalle; Johann Meyer; Martin Forster; Carol Stocking; Anke Wahlers; Oliver Frank; Wolfram Ostertag; Klaus Kühlcke; Hans-Georg Eckert; Boris Fehse; Christopher Baum
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

2.  Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences.

Authors:  Weizhong Li; Adam Godzik
Journal:  Bioinformatics       Date:  2006-05-26       Impact factor: 6.937

3.  Complementary and independent function for Hoxb4 and Bmi1 in HSC activity.

Authors:  A Faubert; J Chagraoui; N Mayotte; M Fréchette; N N Iscove; R K Humphries; G Sauvageau
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2008-11-06

4.  Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Authors:  Africa Gonzalez-Murillo; M Luz Lozano; Eugenio Montini; Juan A Bueren; Guillermo Guenechea
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

5.  Retroviral insertion site analysis in dominant haematopoietic clones.

Authors:  Olga S Kustikova; Ute Modlich; Boris Fehse
Journal:  Methods Mol Biol       Date:  2009

6.  SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling.

Authors:  W Takash; J Cañizares; N Bonneaud; F Poulat; M G Mattéi; P Jay; P Berta
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

7.  Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells.

Authors:  Enrique Samper; Piedad Fernández; Raúl Eguía; Luis Martín-Rivera; Antonio Bernad; María A Blasco; Miguel Aracil
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

8.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy.

Authors:  Yan Shou; Zhijun Ma; Taihe Lu; Brian P Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

9.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

10.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more
  38 in total

Review 1.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Authors:  Perry B Hackett; Elena L Aronovich; David Hunter; Myra Urness; Jason B Bell; Steven J Kass; Laurence J N Cooper; Scott McIvor
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

2.  Gene therapy strategies: can we eradicate HIV?

Authors:  Jan van Lunzen; Boris Fehse; Joachim Hauber
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

3.  Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Authors:  Sebastian Newrzela; Kerstin Cornils; Tim Heinrich; Julia Schläger; Ji-Hee Yi; Olga Lysenko; Janine Kimpel; Boris Fehse; Dorothee von Laer
Journal:  Mol Med       Date:  2011-07-27       Impact factor: 6.354

4.  Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

Authors:  Jason B Bell; Elena L Aronovich; Jeffrey M Schreifels; Thomas C Beadnell; Perry B Hackett
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

5.  Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples.

Authors:  Martijn H Brugman; Julia D Suerth; Michael Rothe; Sebastian Suerbaum; Axel Schambach; Ute Modlich; Olga Kustikova; Christopher Baum
Journal:  Hum Gene Ther Methods       Date:  2013-03-14       Impact factor: 2.396

6.  CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

Authors:  Christopher L Nobles; Scott Sherrill-Mix; John K Everett; Shantan Reddy; Joseph A Fraietta; David L Porter; Noelle Frey; Saar I Gill; Stephan A Grupp; Shannon L Maude; Donald L Siegel; Bruce L Levine; Carl H June; Simon F Lacey; J Joseph Melenhorst; Frederic D Bushman
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

7.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Authors:  Christian Brendel; Walther Hänseler; Vital Wohlgensinger; Matteo Bianchi; Serap Tokmak; Linping Chen-Wichmann; Elena Kuzmenko; Nikola Cesarovic; Flora Nicholls; Janine Reichenbach; Reinhard Seger; Manuel Grez; Ulrich Siler
Journal:  Hum Gene Ther Methods       Date:  2013-05-02       Impact factor: 2.396

8.  Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentiviral vectors.

Authors:  Joerg Enssle; Grant D Trobridge; Kirsten A Keyser; Christina Ironside; Brian C Beard; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

9.  Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

Authors:  Maria Garcia-Gomez; Andrea Calabria; Maria Garcia-Bravo; Fabrizio Benedicenti; Penelope Kosinski; Sergio López-Manzaneda; Collin Hill; María Del Mar Mañu-Pereira; Miguel A Martín; Israel Orman; Joan-LLuis Vives-Corrons; Charles Kung; Axel Schambach; Shengfang Jin; Juan A Bueren; Eugenio Montini; Susana Navarro; Jose C Segovia
Journal:  Mol Ther       Date:  2016-05-03       Impact factor: 11.454

10.  Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.

Authors:  Kerstin B Kaufmann; Christian Brendel; Julia D Suerth; Uta Mueller-Kuller; Linping Chen-Wichmann; Joachim Schwäble; Shweta Pahujani; Hana Kunkel; Axel Schambach; Christopher Baum; Manuel Grez
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.